Company Overview of Cold Spring Harbor Laboratory Inc.
Cold Spring Harbor Laboratory Inc. (CSHL) is a research and educational institution. The company conducts research programs focusing on cancer, neurobiology, plant genetics, genomics, and bio-informatics. It also offers graduate and undergraduate courses in the fields of cancer biology, neuroscience, plant biology, cellular and molecular biology, genetics, macromolecular structure, and bioinformatics. The company is based in Cold Spring Harbor, New York.
1 Bungtown Road
Cold Spring Harbor, NY 11724
Founded in 1963
Key Executives for Cold Spring Harbor Laboratory Inc.
Chief Executive Officer, President and Trustee
Chairman of the Board of Trustees
Compensation as of Fiscal Year 2015.
Cold Spring Harbor Laboratory Inc. Key Developments
Cold Spring Harbor Laboratory Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015
May 4 15
Cold Spring Harbor Laboratory Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015. Venue: Time Warner Center, New York, United States. Presentation Date & Speakers: May-05-2015, Charles Ryan, General Counsel.
Cold Spring Harbor Laboratory and North Shore-LIJ Announce Strategic Affiliation to Accelerate Benefits of Cancer Research to Patients
Apr 2 15
Cold Spring Harbor Laboratory and the North Shore-LIJ Health System announced a strategic affiliation to align CSHL's cancer research with North Shore-LIJ’s growing network of clinical services encompassing more than 16,000 new cancer cases annually across the New York metropolitan area. The CSHL-North Shore-LIJ affiliation will benefit from the investment of more than $120 million to accelerate cancer research, diagnosis and treatment. Funds will be used to advance cancer therapeutics research, develop a new clinical cancer research unit at the North Shore-LIJ Cancer Institute's headquarters in Lake Success, NY to support early-phase clinical studies of new cancer therapies, and recruit and train more clinician-scientists in oncology. The CSHL-North Shore-LIJ affiliation will recruit cancer researchers and clinicians to the region. As part of the collaboration, clinician-scientists will be trained to perform preclinical cancer research and conduct early-stage human clinical trials. Positive findings from this partnership in research and therapeutics will form the basis for advanced-phase clinical trials to be conducted both at North Shore-LIJ facilities and collaborating outside medical centers. Patients cared for at North Shore-LIJ Cancer Institute facilities will benefit from increased access to these innovative clinical studies. The CSHL affiliation is the latest bold step by North Shore-LIJ to improve the coordination of multidisciplinary cancer care. Over the past two years, North Shore-LIJ has already invested more than $175 million to open and expand cancer treatment centers throughout Long Island and New York City. A recently completed $84 million expansion of the Cancer Institute’s headquarters in Lake Success consolidated all cancer services offered by North Shore University Hospital and LIJ Medical Center in a 130,000-square-foot facility, including ambulatory hematology/oncology, chemotherapy and radiation medicine, as well as surgical oncology and brain tumor services. North Shore-LIJ is also building a new $34 million, 45,500-square-foot outpatient cancer center in Bay Shore, NY and is pursuing other major expansions on Long Island and in Manhattan, Queens, Staten Island and Westchester County.
Cold Spring Harbor Laboratory Announces Collaboration with GSK to Develop Treatment for Obesity and Type 2 Diabetes
Mar 23 15
Cold Spring Harbor Laboratory (CSHL) announced a collaboration with GSK to develop a treatment for obesity and type 2 diabetes. Scientists at CSHL and GSK will pursue drug development based on a novel approach to regulate the enzymatic activity of the phosphatase PTP1B. The goal of the multi-year CSHL-GSK collaboration is to identify potent, selective, orally bioavailable small molecules that inhibit PTP1B activity in vivo following stimulation by insulin and leptin, which would be expected to overcome insulin and leptin resistance that is encountered in diabetes and obesity. The work at CSHL will be led by Professor Nicholas Tonks, who is an expert on the protein tyrosine phosphatase (PTP) family of enzymes and their roles in human diseases. GSK and CSHL will provide project co-leadership, allowing synergy between their different sets of expertise to facilitate the development of novel therapeutics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|